Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor

Hemangiopericytomas and malignant solitary fibrous tumors (HPC/SFT) are rare, closely related sarcomas with unpredictable behavior that respond infrequently to chemotherapy. An optimal systemic treatment strategy for advanced HPC/SFT has not yet been identified.

[1]  U. Pastorino,et al.  Evaluation of the antitumor activity of sunitinib malate (SM) in solitary fibrous tumor (SFT). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  D. Araujo,et al.  New insights into the hemangiopericytoma/solitary fibrous tumor spectrum of tumors , 2009, Current opinion in oncology.

[3]  L. Qin,et al.  Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Chamberlain,et al.  SEQUENTIAL SALVAGE CHEMOTHERAPY FOR RECURRENT INTRACRANIAL HEMANGIOPERICYTOMA , 2008, Neurosurgery.

[5]  L. Ellis,et al.  VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.

[6]  J. Goldblum,et al.  Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505 , 2008 .

[7]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[8]  Robin L. Jones,et al.  Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. , 2007, The Lancet. Oncology.

[9]  Haesun Choi,et al.  We should desist using RECIST, at least in GIST. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Haesun Choi,et al.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[12]  C. Fletcher.  The evolving classification of soft tissue tumours: an update based on the new WHO classification , 2006, Histopathology.

[13]  L. Guillou,et al.  Solitary fibrous tumour and haemangiopericytoma: evolution of a concept , 2006, Histopathology.

[14]  F. Spitz,et al.  Hemangiopericytoma: A 20-year single-institution experience , 1998, Annals of Surgical Oncology.

[15]  F. Grosso,et al.  Imatinib mesylate in chordoma , 2004, Cancer.

[16]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[17]  I. McCutcheon,et al.  Intracranial meningeal hemangiopericytoma: The role of radiotherapy , 2004, Cancer.

[18]  R. Benjamin,et al.  A two‐arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas , 2003, Cancer.

[19]  C. Antonescu,et al.  Conventional hemangiopericytoma , 2002, Cancer.

[20]  M. Alifano,et al.  Solitary fibrous tumors of the pleura: clinical characteristics, surgical treatment and outcome. , 2002, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[21]  F. Mertens,et al.  World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone , 2002 .

[22]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[23]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[24]  B. Scheithauer,et al.  Management of recurrent meningeal hemangiopericytoma , 1998, Cancer.

[25]  J. Parisi,et al.  Hemangiopericytoma of the central nervous system: a review of 94 cases. , 1991, Human pathology.

[26]  B. Scheithauer,et al.  Meningeal hemangiopericytoma: histopathological features, treatment, and long-term follow-up of 44 cases. , 1989, Neurosurgery.

[27]  Beadle Gf,et al.  Treatment of advanced malignant hemangiopericytoma with combination adriamycin and dtic: A report of four cases , 1983, Journal of surgical oncology.

[28]  B. Hillcoat,et al.  Treatment of advanced malignant hemangiopericytoma with combination adriamycin and dtic: A report of four cases , 1983, Journal of surgical oncology.

[29]  C. Coltman,et al.  Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. , 1976, Cancer treatment reports.

[30]  B. H. Smith,et al.  Hemangiopericytoma. An analysis of 106 cases. , 1976, Human pathology.

[31]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .